PAVmed (NASDAQ:PAVM) Upgraded by Zacks Investment Research to Hold

PAVmed} stock has undergone multiple analysts rating changes in the recent past.  PAVmed Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More PAVmed (NASDAQ:PAVM) Upgraded by Zacks Investment Research to Hold